Recombinant Rat Muscarinic acetylcholine receptor M2 (Chrm2)

Choosing the Optimal Expression System for Recombinant CHRM2 Production

Question: How do I select between HEK-293 cells, E. coli, and cell-free systems for recombinant CHRM2 expression to ensure proper post-translational modifications and functional activity?

Answer:
Experimental Design Considerations

• HEK-293 Cells (Mammalian):

  • Advantages: Native folding, proper glycosylation, and membrane integration critical for receptor function .

  • Purity: >90% purity via Bis-Tris PAGE, anti-tag ELISA, and SEC-HPLC .

  • Applications: Structural studies, ligand-binding assays requiring native conformation.

• E. coli (Bacterial):

  • Advantages: High yield, cost-effective, ideal for large-scale production of cytoplasmic domains or peptide fragments .

  • Limitations: Lacks eukaryotic PTMs; may form inclusion bodies.

  • Purity: >97% for GST/His-tagged proteins .

• Cell-Free Protein Synthesis (CFPS):

  • Advantages: Flexible for membrane protein production; avoids cellular toxicity.

  • Purity: 70–80% via SDS-PAGE and SEC-HPLC .

Data-Driven Decision Table

Troubleshooting: For HEK-293 systems, optimize transfection reagents (e.g., PEI) and growth media to maximize yield .

Optimizing M2 Receptor Activation Protocols for Functional Studies

Question: How do I design experiments to study M2 receptor activation in primary cells or differentiated adipose-derived stem cells (dASCs), considering agonist specificity and off-target effects?

Answer:
Methodological Approach

• Agonist Selection:

  • Arecaidine propargyl ester (APE): M2-preferred agonist; induces reversible cell cycle arrest in dASCs by downregulating proliferation markers (e.g., c-Jun) and upregulating differentiation markers (e.g., Egr-2) .

  • Carbamylcholine (Cch): Broad muscarinic agonist; synergizes with EGF or FBS to enhance proliferation in airway smooth muscle cells (ASMCs) but inhibits TNF-α-induced growth .

• Experimental Controls:

  • Antagonists:

    • AF-DX-116: M2-specific antagonist; blocks Cch-mediated proliferation in ASMCs .

    • 4-DAMP: M3-specific antagonist; less effective in ASMCs, confirming M2 dominance .

Data Interpretation Challenges
Conflicting outcomes (e.g., growth arrest vs. proliferation) may arise from:

• Cell-Type Specificity: M2 activation inhibits dASC growth but promotes ASMC proliferation .

• Microenvironment: Synergistic growth factors (e.g., EGF) or inflammatory mediators (e.g., TNF-α) modulate receptor responses .

Troubleshooting: Validate receptor expression via Western blot (e.g., CHRM2 antibody PA1325-1, 71 kDa band) and confirm agonist/antagonist specificity with dose-response curves.

Validating Antibody Specificity for CHRM2 in Cross-Species IHC

Question: How do I test the cross-reactivity of anti-CHRM2 antibodies (e.g., PA1325-1) for zebrafish brain IHC, given limited validation data?

Answer:
Methodological Workflow

• Sequence Homology Analysis:

  • BLAST Alignment: Compare immunogen sequence (e.g., human CHRM2) with zebrafish CHRM2. High homology (>80%) suggests potential cross-reactivity .

• Pilot Testing:

  • Sample Prep: Optimize fixation (e.g., paraformaldehyde) and permeabilization (e.g., 0.1% Triton X-100).

  • Antibody Titration: Start at 1:500 dilution; adjust based on background signal.

• Controls:

  • Negative Control: Omit primary antibody.

  • Positive Control: Use rat brain tissue (validated for PA1325-1) .

Expected Outcomes

Troubleshooting: High background may indicate non-specific binding; use blocking buffers (e.g., 5% BSA) or pre-absorption with peptide immunogen.

Analyzing Conflicting Data on M2 Receptor Effects in Proliferation vs. Differentiation

Question: Why do M2 receptor agonists induce growth arrest in dASCs but promote proliferation in ASMCs ? How do I reconcile these findings?

Answer:
Mechanistic Insights

• Cell-Specific Signaling Pathways:

  • dASCs: M2 activation downregulates c-Jun and upregulates Egr-2, favoring differentiation over proliferation .

  • ASMCs: M2 activation synergizes with growth factors (e.g., EGF) via distinct signaling (e.g., PI3K/Akt) .

• Environmental Context:

  Factor	dASCs	ASMCs
  Growth Factors	Absent	Present (EGF, FBS)
  Inflammatory Cues	Absent	Present (TNF-α)
  Outcome	Growth Arrest	Proliferation

Experimental Design Recommendations

• Isolate Variables: Test receptor activation in serum-free vs. serum-rich media.

• Biomarker Profiling: Quantify c-Jun, Egr-2 (differentiation) and ERK, Akt (proliferation) via qPCR or phospho-specific antibodies.

Functional Assays for Assessing Recombinant CHRM2 Activity

Question: What functional assays are most effective for validating recombinant CHRM2 activity in vitro?

Answer:
Assay Selection and Optimization

• Ligand-Binding Assays:

  • [³H]-Acetylcholine Binding: Quantify receptor affinity (Kd).

  • Fluorescence-Based Assays: Use fluorescently labeled agonists (e.g., Alexa Fluor-conjugated ACh).

• Signaling Pathway Activation:

  • G Protein-Coupled Response: Measure intracellular cAMP levels (e.g., via ELISA) inhibited by M2 activation.

  • Ion Channel Modulation: Patch-clamp recordings to assess potassium channel activity.

• Cellular Functional Assays:

  • Proliferation (MTS-PMS): Assess growth in ASMCs .

  • Migration (Scratch Assay): Evaluate inhibition in dASCs .

Troubleshooting: For low signal, ensure proper receptor membrane integration (validate via confocal imaging with CHRM2 antibodies) .

Structural Insights for CHRM2-Ligand Interactions

Question: How can I leverage recombinant CHRM2 for structural studies to map binding sites of muscarinic agonists/antagonists?

Answer:
Methodological Approach

• Cryo-EM or X-Ray Crystallography:

  • Purification: Use His-tagged CHRM2 from HEK-293 cells (purity >90%) .

  • Stabilization: Co-express with nanobodies or fusion partners (e.g., maltose-binding protein).

• Mutagenesis and Binding Studies:

  • Site-Directed Mutagenesis: Target conserved residues in the orthosteric binding pocket (e.g., Asp147, Tyr148).

  • Competitive Binding Assays: Measure displacement of radiolabeled ligands by mutants.

• Computational Modeling:

  • Docking Studies: Predict agonist/antagonist poses using crystal structures of related muscarinic receptors.

Challenges: Low-resolution structures may obscure side-chain interactions; validate with mutagenesis data.

Therapeutic Target Validation for CHRM2 in Neurological/Respiratory Diseases

Question: How can I validate CHRM2 as a therapeutic target in vivo using recombinant systems?

Answer:
Preclinical Validation Strategies

• In Vitro Models:

  • Neuroregeneration: Test CHRM2 agonists in dASC differentiation assays .

  • Airway Hyperresponsiveness: Assess ASMC proliferation modulation by CHRM2 antagonists .

• In Vivo Models:

  • Nerve Injury: Overexpress CHRM2 in Schwann cells to enhance remyelination.

  • Asthma: Administer M2 antagonists (e.g., AF-DX-116) in ovalbumin-challenged rats.

• Biomarker Development:

  • CHRM2 Expression: Quantify receptor levels in patient biopsies via IHC (PA1325-1 antibody) .

Data Analysis: Use multivariate models to correlate CHRM2 expression with disease severity.

Addressing Heterogeneity in Recombinant CHRM2 Preparations

Question: How do I ensure batch consistency in recombinant CHRM2 for longitudinal studies?

Answer:
Quality Control Protocols

• Purity Assessment:

  • SDS-PAGE + Coomassie Staining: Verify ~45–71 kDa bands (depending on tags) .

  • SEC-HPLC: Confirm monomeric state (e.g., elution at ~150–200 kDa) .

• Functional Testing:

  • Ligand Binding: Normalize activity across batches using EC50 values for APE or Cch.

  • Cellular Assays: Standardize proliferation/differentiation responses in dASCs or ASMCs.

• Storage Optimization:

  • Lyophilized Form: Reconstitute with stabilizing agents (e.g., glycerol, BSA) to prevent aggregation.

Troubleshooting: Lot-to-lot variability may require re-optimizing protocols; use orthogonal methods (e.g., NMR) for structural validation.

Cross-Talk Between CHRM2 and Other Muscarinic Receptors

Question: How do I differentiate CHRM2-specific effects from pan-muscarinic responses in complex biological systems?

Answer:
Experimental Strategies

• Receptor Knockout/Knockdown:

  • CRISPR-Cas9: Generate CHRM2-KO cells; compare responses to agonists/antagonists.

  • siRNA: Validate knockdown efficiency via qPCR or Western blot .

• Antagonist Combinations:

  • M2-Selective: AF-DX-116 (blocks CHRM2) .

  • M3-Selective: 4-DAMP (controls for off-target effects) .

• BRET/FRET Assays:

  • G Protein Coupling: Monitor β-arrestin recruitment specific to CHRM2.

Data Interpretation: Use hierarchical clustering to identify CHRM2-dependent pathways vs. shared muscarinic signals.

Leveraging CHRM2 for Drug Discovery in CNS Disorders

Question: What high-throughput screening (HTS) platforms are suitable for identifying CHRM2 modulators?

Answer:
HTS Strategies

• Cell-Based Assays:

  • Fluorometric Imaging Plate Reader (FLIPR): Measure intracellular calcium mobilization (indirect readout of Gq/11 coupling).

  • Beta-Lactamase Reporter Gene Assays: Track cAMP levels inhibited by CHRM2 activation.

• Biophysical Assays:

  • Thermal Shift Assays (TSA): Screen for ligands stabilizing CHRM2.

  • Surface Plasmon Resonance (SPR): Measure real-time binding kinetics.

• Virtual Screening:

  • Docking: Use CHRM2 homology models to predict ligand binding.

  • Ensemble Docking: Account for receptor flexibility.

Challenges: HTS may miss allosteric modulators; combine with orthogonal assays (e.g., radioligand binding).